Previous 10 | Next 10 |
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO, will present at the JMP Securities Life Scie...
2023-04-06 17:40:21 ET AN2 Therapeutics ( NASDAQ: ANTX ) on Thursday filed for a mixed shelf offering of up to $300M. The offering may include common stock, preferred stock, debt securities and warrants. The filing does not necessarily indicate that a sale has beg...
2023-03-29 17:09:48 ET AN2 Therapeutics press release ( NASDAQ: ANTX ): Q4 GAAP EPS of -$0.61. Cash, cash equivalents and investments totaled $99.3 million at December 31, 2022, Net loss: For the three months and full year ended December 31, 2022 net loss was $11.8 mil...
Approaching 60 clinical sites participating in pivotal Phase 2/3 trial of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease to date Opened up sites in three additional countries -- Japan, South Korea, and Australia in addition to the U.S.; Japan has some ...
2023-03-23 12:47:58 ET Gainers: DiamondHead Holdings ( DHHCU ) +111% . DiamondHead Holdings ( DHHC ) +91% . Boxed BOXD +88% . ZyVersa Therapeutics ZVSA +33% . Amprius Technologies ( AMPX ) +30% . Kineta ( KA ) +29% . ...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in March. ...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the SVB Securities Global Bio...
AN2 Therapeutics press release ( NASDAQ: ANTX ): Q3 GAAP EPS of -$0.59 in-line. Cash, cash equivalents and investments totaled $106.4M on September 30, 2022. The Company expects that current cash, cash equivalents and investments will be sufficient to fund its ope...
U.S. Enrollment Ongoing in EBO-301 Pivotal Phase 2/3 Clinical Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Plan to Include Japanese Patients in Trial Awarded Contract from NIAID Valued Up to $17.8 Million to Advance Development of Epetraborole for Acute Syst...
MENLO PARK, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will par...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determi...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...